On this Science phase, we look at the European Medicines Company’s current resolution to advocate granting advertising authorization for the anti-Alzheimer’s drug lecanemab. This follows an earlier rejection of its commercialization, citing issues that the dangers outweighed the advantages. So, what modified, and is that this drug actually the miracle therapy for Alzheimer’s that some declare it to be?
Source link
